Tesamorelin & Ipamorelin Blend

The Tesamorelin and Ipamorelin blend appears to exert its potential through distinct yet complementary proposed mechanisms of action. Tesamorelin, a GHRH analog, appears to act by binding to and activating the GHRH receptor on somatotrophs, stimulating synthesis and secretion of endogenous GH in a pulsatile manner. Ipamorelin, a GHSR agonist, activates GHSR in the hypothalamus and peripheral tissues, exhibiting high selectivity without interfering with other hormones. When combined, these peptides may provide a synergistic impact by targeting different components of the growth hormone axis, potentially amplifying overall GH effects on body composition, lipid profile, and insulin sensitivity.

The blend appears to exhibit notable impact on the pituitary gland, a critical endocrine organ responsible for regulation of growth hormone secretion. Tesamorelin may potentially cause a 69% increase in total growth hormone levels assessed via area under the curve and a purported 55% increase in the mean pulse area of growth hormone, without reportedly affecting growth hormone pulse frequency or peak levels. Ipamorelin may have exhibited a propensity to elevate growth hormone levels, potentially reaching heights of up to 80 mIU/l, which when expressed as a percentage increase compared to placebo appears to surpass a 60-fold augmentation.

Research studies frequently indicate that lipodystrophy is often accompanied by insulin resistance, dyslipidemia, and an increased risk of cardiovascular complications. Clinical studies have suggested that Tesamorelin presentation in lipodystrophic test subjects might lead to a reduction in visceral adipose tissue and improvements in insulin sensitivity and lipid profiles. Tesamorelin appears to act through activation of GHRHR, potentially stimulating endogenous growth hormone secretion and promoting lipolysis, while reportedly preserving abdominal subcutaneous adipose tissue and improving body image and lipids.

The potential effects of Tesamorelin on muscle tissue integrity were assessed utilizing computed tomography scans, with results positing a relationship between Tesamorelin and enhancements in muscle density and size. Certain muscle groups, notably the rectus abdominis, psoas major, and paraspinal muscles, appeared to display more pronounced changes, characterized by either augmentation in muscle density and size or a diminution in fat content, with these changes statistically distinct compared to placebo.